FT : Goldman Sachs expects SpaceX’s AI revenue to surge 100 times by 2030

Goldman Sachs expects SpaceX’s AI revenue to surge 100 times by 2030
Projections by Wall Street bank underpin the $1.78tn valuation group is pitching in IPO

SpaceX’s pitch to achieve a $1.78tn valuation in its initial public offering hinges on revenues at its AI unit surging by around 100 times by 2030, according to projections made by its lead investment bank Goldman Sachs.

Goldman expects revenues from SpaceX’s AI division to rise to $322bn by 2030 from $3.2bn in 2025, according to forecasts discussed by the Wall Street bank with a potential investor in the deal. SpaceX’s total revenue is expected to reach $474bn in 2030 from $18.7bn last year.

The bank’s lofty projections underscore the aggressive bets underpinning the AI investment boom by Big Tech firms that has propelled the US stock market to a series of record highs. Goldman’s model was verbally shared with the investor as SpaceX kicks off its IPO roadshow, in which bankers will seek to sell money managers on a deal that could raise up to $86bn.

The valuation of Elon Musk’s rockets-to-chatbot group rests on an assumption that its AI division xAI — which made a loss of $6.4bn in 2025 — has a total addressable market of $26.5tn, SpaceX’s IPO prospectus shows. That dwarfs the roughly $2tn total addressable market outlined for the group’s Starlink internet service and space operations.

Goldman’s projections show that the Wall Street bank expects revenues at SpaceX’s AI segment to rise 388 per cent to $15.6bn in 2026 compared with the year prior and reach $34.5bn in 2027. The estimates were confirmed by a person familiar with the matter.

SpaceX did not respond to a request for comment. Goldman declined to comment.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • PVH -21%, NTSK -18.6% (also CFO to retire), AVGO -14.8%, WOOF -11.8%, FIVE -10.7%, CRWD -10.1% (also 4-for-1 stock split), CIEN -6.1%, VEEV -5.6%, XE -2.5%, CMCO -2.1%, DSGX -1.2%
Other news:
  • ADCT -49.4% (topline data from its Phase 3 LOTIS-5 trial evaluating ZYNLONTA)
  • DDD -14.4% (prices offering of 16,393,443 shares of common stock at $3.05 per share)
  • AEVA -12.9% (prices follow-on offering of 4,494,382 shares of common stock at $22.25 per share)
  • JBIO -10.1% (prices 10.0 mln shares of common stock at $15.00 per share)
  • LGIH -4.9% (reports May closings)
  • BTSG -4.7% (prices secondary offering of 15.0 mln shares of common stock at $58.75 per share with company buyback)
  • CUE -4.3% (stock offering by selling shareholders)
  • TAC -4.1% (TAC to acquire two gas assets in Colorado for $1 bln from BX and concurrent $350 mln bought deal offering)
  • AVEX -2.5% (prices offering of 8.0 mln shares of common stock at $27.00 per share)
  • BMNR -2.5% (launches preferred stock offering to fund Ethereum strategy)
  • XPO -2% (LTL segment operating metrics for May)
  • ALVO -1.9% (resubmits U.S. applications for Simponi and Eylea biosimilars)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • TLYS +18.5%, CAL +10%, AI +0.8%, BKE +0.5% (May comps)
Other news:
  • VSTM +5.2% (FDA grants Fast Track Designation for VS-7375)
  • RCEL +4.7% (stockholders approved of the issuance of equity securities)
  • SNY +3.4% (launches 2026 employee stock purchase plan)
  • GLBE +3.1% (authorization of $500 mln share repurchase program)
  • ZSQR +2.6% (entered into a $50 mln committed equity forward purchase agreement with LucentHash / Data Part Capital, a trading name of Translucent Matter)
  • PHAR +2.1% (receives FDA acceptance for pediatric Joenja filing)
  • COST +2% (May same store comps)
  • MCHP +2% (received approval from the U.S. Department of Commerce's Bureau of Industry and Security for an export license authorizing the use of advanced technology under Export Control Classification Number 3E001 and related high-performance hardware under ECCN?3A001.a.7.b.)
  • GNK +1.9% (issues letter to shareholders)
  • NVS +1.7% (IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years)
  • GHRS +1.6% (reports publication of Phase 2a Postpartum Depression Results)
  • ODC +1.5% (increases dividend; also authorizes 500,000 share repurchase program)
  • IPI +1.2% (increases share repurchase authorization to $50 mln from $35 mln)
  • TV +1.2% (issued zero-coupon mandatory convertible debentures into shares in the amount of $6,917,800,007.42 Mexican pesos)
  • EL +1.1% (increases expected charge related to restructuring program)
  • ADSK +1.1% (collaboration with Amazon Web Services)
  • ZG +1% (authorizes additional $1.25 bln in repurchases; also amends repurchase program to limit any shareholder to 45% voting power)
  • BIIB +1% (Biogen and UCB present additional Phase 3 lupus data for dapirolizumab pegol)

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Erasca (ERAS) upgraded to Neutral from Underperform at BofA Securities, tgt $16
    • Essent Group (ESNT) upgraded to Outperform from Market Perform at Keefe Bruyette, tgt $73
    • Expro Group (XPRO) upgraded to Buy from Neutral at Goldman
    • Karat Packaging (KRT) upgraded to Outperform from Market Perform at William Blair
    • Medtronic (MDT) upgraded to Buy from Neutral at BTIG Research, tgt $90
    • Murphy Oil (MUR) upgraded to Overweight from Sector Weight at KeyBanc, tgt $48
    • Oscar Health (OSCR) upgraded to Equal Weight from Underweight at Wells Fargo, tgt $20
    • Plains All American (PAA) upgraded to Neutral from Sell at Goldman, tgt $24
    • Plains GP Holdings (PAGP) upgraded to Neutral from Sell at Goldman, tgt $24
    • RTX (RTX) upgraded to Buy from Hold at Jefferies, tgt $220
    • UnitedHealth Group (UNH) upgraded to Buy from Neutral at BofA Securities, tgt $450
    • Venture Global (VG) upgraded to Overweight from Neutral at JPMorgan, tgt $17
  • Downgrades:
    • ADC Therapeutics (ADCT) downgraded to Sector Perform from Outperform at RBC Capital, tgt $2
    • Broadcom (AVGO) downgraded to Neutral from Outperform at Macquarie, tgt $437
    • CMS Energy (CMS) downgraded to Hold from Buy at Jefferies, tgt $74
    • Commercial Metals (CMC) downgraded to Equal Weight from Overweight at Wells Fargo, tgt $77
    • Ecopetrol (EC) downgraded to Neutral from Buy at Citigroup, tgt $18
    • EHang (EH) downgraded to Neutral from Buy at UBS, tgt $11.10
    • Ollie's Bargain Outlet (OLLI) downgraded to Accumulate from Buy at Gordon Haskett
    • PVH Corp. (PVH) downgraded to In Line from Outperform at Evercore ISI, tgt $79
    • Smith & Nephew (SNN) downgraded to Hold from Buy at Kepler Cheuvreux
  • Others:
    • Absci (ABSI) initiated with an Outperform at Leerink, tgt $12
    • Axalta Coating Systems (AXTA) reinstated with a Buy at Citigroup, tgt $44
    • Cipher Mining (CIFR) initiated with an Outperform at Bernstein, tgt $32
    • CoStar Group (CSGP) initiated with a Buy at Benchmark, tgt $45
    • FedEx Freight (FDXF) initiated with an Outperform at Evercore ISI, tgt $168
    • Opus Genetics (IRD) initiated with a Buy at Guggenheim, tgt $16
    • Pulse Biosciences (PLSE) initiated with a Buy at Canaccord, tgt $32
    • Radiopharm Theranostics (RADX) initiated with a Buy at H.C. Wainwright, tgt $6
    • Sherwin-Williams (SHW) reinstated with a Buy at Citigroup, tgt $355
    • TeraWulf (WULF) initiated with an Outperform at Bernstein, tgt $46

FT : Trafigura warns oil at ‘inflection point’ as Iran war stokes bumper half-ye

Trafigura warns oil at ‘inflection point’ as Iran war stokes bumper half-year profits
Commodity trader’s net profit more than doubles to $4.1bn for October to March period

Commodities trader Trafigura has warned that global energy markets are at an “inflection point” that could send prices sharply higher as it reported near-record first-half profits boosted by the war in the Middle East.

The group’s net profit for the six months to March 31 climbed to $4.1bn, more than double the same period last year — and the second highest in its history, just below the $5.5bn made in the first half of 2023 in the aftermath of Russia’s invasion of Ukraine.

Trafigura’s results are an early indication of how the trading houses that move raw materials around the world are expecting bonanza profits from the Iran war, which has largely shut the Strait of Hormuz since late February, disrupting the flow of as much as a fifth of the world’s oil.

While the privately held group’s profits announced on Thursday capture only the first month of the war, trading houses typically benefit from periods of disruption and volatility as they profit from dislocations in the prices of commodities between different geographic locations.

Trafigura and rivals such as Vitol, Mercuria and Gunvor all reported record profits during 2022 and 2023 after Russia’s full-scale invasion of Ukraine roiled energy markets.

Oil prices surged in the early days of the Iran war but since then prices have broadly been lower than many traders first anticipated, with Brent crude, the international benchmark, falling back below $100 a barrel.

Trafigura warned markets against complacency, with chief economist Saad Rahim arguing that the world had largely run through its “buffers” of fuel inventories and now stood “at an inflection point”.

The war in the Middle East has caused a production loss of about 14mn barrels per day, compared with pre-conflict levels, according to Rahim, who added that the price response did not reflect the magnitude of the energy crisis.

“The factors that have contained prices so far — elevated inventories, floating cargoes, co-ordinated SPR [strategic petroleum reserve] releases, a shoulder season, and demand destruction across Asia and Africa — have bought the market time, but are not a solution,” Rahim wrote in the report.

He pointed to low US petrol inventories as a particular concern, noting that these inventories are being drawn down at a record pace.

Even if a peace deal between the Trump administration and Tehran was reached soon, “restoring production and shipping flows to pre-conflict levels will, by most estimates, take months, not weeks”, Rahim added.

Trafigura chief executive Richard Holtum echoed Rahim’s view, saying “the pressures that have built up across commodity markets and global supply chains in recent months will take time to unwind”.

Trafigura, whose financial year runs until the end of September, said that during its first-half period its traders moved record volumes of oil and gas, equivalent to 8.7mn b/d, up 21 per cent from the same period a year prior.

The company’s involvement in Venezuela, where the US removed leader Nicolás Maduro in January, also contributed to its increased oil volumes, accounting for about 300,000 b/d.

Chief financial officer Stephan Jansma said the company had a particularly strong first quarter (ending December 31), its second-most profitable first quarter ever. Trafigura’s metals division benefited from the copper tariffs in place in the US, and its refineries reported unusually strong results in the quarter, the company said.

“A substantial portion of the period’s profits had already been secured before the conflict in the Middle East began at the end of February 2026,” Jansma wrote.

>>> Europe : Brokers Upgrades & Downgrades - 4th of June 2026 V2(+)

>>> Up
* Clas Ohlson Raised to Buy at SEB Equities; PT 425 kronor
* FLSmidth Raised to Buy at BofA
* Puma Raised to Buy at Citi; PT 35 euros
* Rockwool Raised to Buy at Nordea; PT 230 kroner
* Wartsila Raised to Neutral at Goldman; PT 34 euros

>>> Down
* Barry Callebaut Cut to Neutral at Goldman; PT 1,210 Swiss francs
* Lonza Cut to Sell at Intron Health; PT 440 Swiss francs (+)
* PSP Swiss Cut to Sell at Van Lanschot Kempen
* PVH Cut to Inline at Evercore ISI; PT $79
* Smith & Nephew Cut to Hold at Kepler Cheuvreux (+)

>>> Initiation
* Akzo Nobel Resumed Buy at Citi; PT 61 Swiss francs
* Autotrader Group PLC Rated New Buy at Goldman (+)
* Oeneo Rated New Outperform at Oddo BHF; PT 11.50 euros
* Prosus Rated New Neutral at Goldman (+)
* Rightmove Rated New Neutral at Goldman (+)
* Santhera Rated New Buy at Stifel; PT 25 Swiss francs
* Scout24 Rated New Buy at Goldman (+)
* Sylvania Platinum Rated New Outperform at RBC; PT 175 pence

>>> Call
* Goldman Cuts Barry Callebaut to Neutral on Industry Overcapacity (+)
* Defense Stocks Losing Steam as Catalysts Fade, Bernstein Says
* Oeneo Poised for Gradual Recovery, New Outperform at Oddo BHF
* Puma Raised to Buy at Citi on Major China Growth Opportunity
* Wartsila Raised to Neutral at Goldman on Capacity Increases (+)

>>> STOXX announces changes in DAX, MDAX, SDAX and TecDAX; new index adjustments

STOXX announces changes in DAX, MDAX, SDAX and TecDAX; new index adjustments will become effective on 22-Jun-26

• DAX:
o Addition: Hochtief
o Deletion: Porsche Automobil Holding SE

• MDAX:
o Addition: Porsche Automobil Holding SE, Elmos Semiconductor SE, Siltronic AG, SUSS MicroTec SE
o Deletion: Hochtief, Redcare Pharmacy N.V., Ströer SE & Co. KGaA, Jungheinrich AG

• SDAX:
o Addition: Jungheinrich AG, Ströer SE & Co. KGaA, Redcare Pharmacy N.V., LPKF Laser & Electronics SE, VINCORION SE, Basler AG, ASTA ENERGY SOLUTIONS AG
o Deletion: SUSS MicroTec SE, Siltronic AG, Elmos Semiconductor SE, adesso SE, Borussia Dortmund GmbH & Co. KGaA, Verve Group SE, ProSiebenSat.1 Media SE

• TecDAX:
o Addition: PVA TePla AG, Verbio SE
o Deletion: Nagarro SE, 1&1 AG